Literature DB >> 10975554

New technologies in cervical cancer precursor detection.

M E Soler1, P D Blumenthal.   

Abstract

The current literature reflects three routes toward improving cervical cancer screening. The first is to improve the test qualities of cytology-based screening. The use of liquid-based cytology and computerized analysis of Papanicolaou tests are examples of attempts at this approach. Secondly, through various combinations of parallel or sequential tests, either the sensitivity or the specificity of a given test could be improved depending on the tests chosen and the order in which they were performed (eg, Papanicolaou test followed by human papillomavirus [HPV] or vice versa). Several excellent studies have been published this year on the use of HPV DNA testing as a primary screening modality and as an adjunct to the triage of mildly abnormal cytologic findings. The recent literature also reflects increasing interest in visual inspection of the cervix and self-collected samples for HPV testing as an equally effective and viable alternative to cytology in low-resource settings. A third possibility is to make use of advances in digital and spectroscopic techniques. In these cost-conscious times, a significant number of articles address the cost-effectiveness of these technologies and the real value of cervical cancer screening. This article reviews the current literature concerning both the advent of new cervical cancer screening technologies and the rediscovery of old ones.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975554     DOI: 10.1097/00001622-200009000-00013

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  1 in total

1.  Correlation between the digital cervicography and pathological diagnosis performed at private clinics in Korea.

Authors:  Seog-Nyeon Bae; Jin-Hwi Kim; Chung-Won Lee; Min-Jong Song; Eun-Kyung Park; Yong-Seok Lee; Keun-Ho Lee; Soo-Young Hur; Joo-Hee Yoon; Sung-Jong Lee
Journal:  Int J Med Sci       Date:  2012-10-04       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.